Skip to main content
Clinical Trials/NCT04741048
NCT04741048
Withdrawn
N/A

A Pre-market, Open-label Feasibility, Prospective, Single-arm Multicenter Feasibility Investigation of Hearing Performance Using the CI624 in Adults With Low-frequency Residual Hearing.

Cochlear1 site in 1 countryMarch 8, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Sensorineural Hearing Loss
Sponsor
Cochlear
Locations
1
Primary Endpoint
Characterize hearing performance of the CI624.
Status
Withdrawn
Last Updated
4 years ago

Overview

Brief Summary

The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI624 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.

Registry
clinicaltrials.gov
Start Date
March 8, 2021
End Date
April 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Cochlear
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 years-of-age or older at the time of surgery.
  • Low-frequency threshold at 500 Hz ≤ 50 dB HL and high-frequency pure-tone average (PTA), 2000-8000 Hz ≥ 65 dB HL in the ear to be implanted.
  • Pure-tone average (PTA) (0.5k, 1k, 2k Hz) \> 30 dB HL in the contralateral ear.
  • CNC word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤ 80% in the contralateral ear.
  • English spoken as a primary language.
  • Willing and able to provide written informed consent.

Exclusion Criteria

  • Individuals older than 70 years at the time of surgery.
  • Duration of severe to profound sensorineural hearing loss \> 20 years per self-report.
  • Onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age.
  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
  • Conductive overlay of 15 dB or greater at two or more frequencies, in the range of 250 through 1000 Hz in the ear to be implanted.
  • Hearing loss of neural or central origin.
  • Diagnosis of Auditory Neuropathy.
  • Active middle-ear infection.
  • Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator.
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the Investigator.

Outcomes

Primary Outcomes

Characterize hearing performance of the CI624.

Time Frame: 14 months

Hearing performance of the CI624 will characterized using Constant Nucleus Constant (CNC) word recognition in quiet. Performance is scored as percent correct words.

Study Sites (1)

Loading locations...

Similar Trials